OTCMKTS:WHCA

Williston Competitors

$0.70
+0.45 (+180.00 %)
(As of 03/31/2021)
Add
Compare
Today's Range
$0.70
Now: $0.70
$0.70
50-Day Range
$0.25
MA: $0.33
$0.70
52-Week Range
$0.10
Now: $0.70
$3.00
Volume100 shs
Average Volume720 shs
Market Capitalization$9.51 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.09

Competitors

Williston (OTCMKTS:WHCA) Vs. MSLP, PHIO, NBY, VICP, IMRN, and EYEG

Should you be buying WHCA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Williston, including MusclePharm (MSLP), Phio Pharmaceuticals (PHIO), NovaBay Pharmaceuticals (NBY), Vicapsys Life Sciences (VICP), Immuron (IMRN), and EyeGate Pharmaceuticals (EYEG).

Williston (OTCMKTS:WHCA) and MusclePharm (OTCMKTS:MSLP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.

Insider & Institutional Ownership

16.7% of MusclePharm shares are held by institutional investors. 60.7% of MusclePharm shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Williston and MusclePharm, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Williston0000N/A
MusclePharm0000N/A

Risk & Volatility

Williston has a beta of -1.09, meaning that its stock price is 209% less volatile than the S&P 500. Comparatively, MusclePharm has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500.

Valuation & Earnings

This table compares Williston and MusclePharm's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
WillistonN/AN/AN/AN/AN/A
MusclePharm$79.67 million0.47$-18,930,000.00N/AN/A

Williston has higher earnings, but lower revenue than MusclePharm.

Profitability

This table compares Williston and MusclePharm's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
WillistonN/AN/AN/A
MusclePharm-4.64%N/A-25.00%

Summary

MusclePharm beats Williston on 4 of the 6 factors compared between the two stocks.

Williston (OTCMKTS:WHCA) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.

Risk & Volatility

Williston has a beta of -1.09, indicating that its share price is 209% less volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 2.31, indicating that its share price is 131% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Williston and Phio Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Williston0000N/A
Phio Pharmaceuticals00103.00

Phio Pharmaceuticals has a consensus target price of $4.00, indicating a potential upside of 45.99%. Given Phio Pharmaceuticals' higher possible upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Williston.

Earnings and Valuation

This table compares Williston and Phio Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
WillistonN/AN/AN/AN/AN/A
Phio Pharmaceuticals$20,000.001,853.88$-8,910,000.00($19.33)-0.14

Williston has higher earnings, but lower revenue than Phio Pharmaceuticals.

Profitability

This table compares Williston and Phio Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
WillistonN/AN/AN/A
Phio PharmaceuticalsN/A-70.64%-59.16%

Insider and Institutional Ownership

1.8% of Phio Pharmaceuticals shares are owned by institutional investors. 0.5% of Phio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Phio Pharmaceuticals beats Williston on 6 of the 8 factors compared between the two stocks.

Williston (OTCMKTS:WHCA) and NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Williston and NovaBay Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Williston0000N/A
NovaBay Pharmaceuticals0000N/A

Profitability

This table compares Williston and NovaBay Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
WillistonN/AN/AN/A
NovaBay Pharmaceuticals-122.78%-309.15%-93.80%

Risk & Volatility

Williston has a beta of -1.09, indicating that its share price is 209% less volatile than the S&P 500. Comparatively, NovaBay Pharmaceuticals has a beta of 3.5, indicating that its share price is 250% more volatile than the S&P 500.

Insider and Institutional Ownership

2.7% of NovaBay Pharmaceuticals shares are owned by institutional investors. 1.8% of NovaBay Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Williston and NovaBay Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
WillistonN/AN/AN/AN/AN/A
NovaBay Pharmaceuticals$6.60 million5.57$-9,650,000.00($0.48)-1.83

Williston has higher earnings, but lower revenue than NovaBay Pharmaceuticals.

Summary

NovaBay Pharmaceuticals beats Williston on 4 of the 7 factors compared between the two stocks.

Vicapsys Life Sciences (OTCMKTS:VICP) and Williston (OTCMKTS:WHCA) are both small-cap construction companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, valuation, risk, analyst recommendations and institutional ownership.

Risk and Volatility

Vicapsys Life Sciences has a beta of 3.47, indicating that its stock price is 247% more volatile than the S&P 500. Comparatively, Williston has a beta of -1.09, indicating that its stock price is 209% less volatile than the S&P 500.

Profitability

This table compares Vicapsys Life Sciences and Williston's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vicapsys Life SciencesN/AN/AN/A
WillistonN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for Vicapsys Life Sciences and Williston, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vicapsys Life Sciences0000N/A
Williston0000N/A

Earnings & Valuation

This table compares Vicapsys Life Sciences and Williston's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vicapsys Life SciencesN/AN/AN/AN/AN/A
WillistonN/AN/AN/AN/AN/A

Summary

Vicapsys Life Sciences beats Williston on 1 of the 1 factors compared between the two stocks.

Immuron (NASDAQ:IMRN) and Williston (OTCMKTS:WHCA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, analyst recommendations, earnings, valuation and risk.

Analyst Ratings

This is a summary of recent ratings for Immuron and Williston, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immuron0000N/A
Williston0000N/A

Profitability

This table compares Immuron and Williston's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmuronN/AN/AN/A
WillistonN/AN/AN/A

Insider and Institutional Ownership

1.6% of Immuron shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk & Volatility

Immuron has a beta of 2.42, meaning that its stock price is 142% more volatile than the S&P 500. Comparatively, Williston has a beta of -1.09, meaning that its stock price is 209% less volatile than the S&P 500.

Valuation & Earnings

This table compares Immuron and Williston's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immuron$1.69 million19.80$-1,970,000.00N/AN/A
WillistonN/AN/AN/AN/AN/A

Williston has lower revenue, but higher earnings than Immuron.

Summary

Immuron beats Williston on 3 of the 3 factors compared between the two stocks.

Williston (OTCMKTS:WHCA) and EyeGate Pharmaceuticals (NASDAQ:EYEG) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Institutional & Insider Ownership

41.1% of EyeGate Pharmaceuticals shares are owned by institutional investors. 57.0% of EyeGate Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Williston and EyeGate Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
WillistonN/AN/AN/A
EyeGate PharmaceuticalsN/A-112.84%-78.83%

Analyst Ratings

This is a breakdown of current ratings for Williston and EyeGate Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Williston0000N/A
EyeGate Pharmaceuticals00203.00

EyeGate Pharmaceuticals has a consensus price target of $12.1250, suggesting a potential upside of 162.45%. Given EyeGate Pharmaceuticals' higher probable upside, analysts plainly believe EyeGate Pharmaceuticals is more favorable than Williston.

Valuation and Earnings

This table compares Williston and EyeGate Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
WillistonN/AN/AN/AN/AN/A
EyeGate Pharmaceuticals$2.69 million12.19$-7,100,000.00($2.23)-2.07

Williston has higher earnings, but lower revenue than EyeGate Pharmaceuticals.

Volatility and Risk

Williston has a beta of -1.09, suggesting that its share price is 209% less volatile than the S&P 500. Comparatively, EyeGate Pharmaceuticals has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.

Summary

EyeGate Pharmaceuticals beats Williston on 6 of the 8 factors compared between the two stocks.


Williston Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
MusclePharm logo
MSLP
MusclePharm
0.6$1.09+0.0%$37.44 million$79.67 million0.00Gap Down
Phio Pharmaceuticals logo
PHIO
Phio Pharmaceuticals
1.8$2.74+1.1%$37.08 million$20,000.00-0.41Gap Up
NovaBay Pharmaceuticals logo
NBY
NovaBay Pharmaceuticals
0.6$0.88+1.1%$36.77 million$6.60 million-2.10
VICP
Vicapsys Life Sciences
0.0$2.00+0.0%$34.97 millionN/A0.00
Immuron logo
IMRN
Immuron
0.5$5.89+1.9%$33.46 million$1.69 million0.00
EyeGate Pharmaceuticals logo
EYEG
EyeGate Pharmaceuticals
1.7$4.62+1.5%$32.79 million$2.69 million-2.30
Abliva AB (publ) logo
NEVPF
Abliva AB (publ)
0.5$0.12+1.1%$32.33 million$10,000.00-2.37
EMBI
Emerald Bioscience
0.5$0.09+1.7%$32.17 millionN/A-1.13Gap Down
INBP
Integrated BioPharma
1.2$1.08+0.0%$32.13 million$52.77 million9.25
Auris Medical logo
EARS
Auris Medical
0.5$4.31+9.7%$31.96 millionN/A-1.87High Trading Volume
Gap Up
Generex Biotechnology logo
GNBT
Generex Biotechnology
0.7$0.28+1.9%$31.78 million$2.66 million-0.63
ATHE
Alterity Therapeutics
0.2$1.39+1.4%$31.42 million$90,000.000.00
PTPI
Petros Pharmaceuticals
0.3$3.13+1.6%$30.57 millionN/A-0.82
Endonovo Therapeutics logo
ENDV
Endonovo Therapeutics
0.4$0.03+1.9%$29.98 million$80,000.000.00
GeoVax Labs logo
GOVX
GeoVax Labs
0.7$4.71+5.7%$29.74 million$1.18 million0.00High Trading Volume
Gap Down
InMed Pharmaceuticals logo
INM
InMed Pharmaceuticals
1.7$3.63+6.9%$29.23 millionN/A0.00Gap Down
RegeneRx Biopharmaceuticals logo
RGRX
RegeneRx Biopharmaceuticals
0.6$0.22+2.9%$29.21 million$80,000.000.00Gap Up
WIZP
Wize Pharma
0.6$0.88+2.3%$29.09 millionN/A-1.96Gap Down
MTP
Midatech Pharma
0.7$2.29+5.7%$29.03 million$860,000.000.00Gap Down
Mallinckrodt logo
MNKKQ
Mallinckrodt
0.8$0.34+0.9%$28.31 million$3.16 billion-0.01
Provectus Biopharmaceuticals logo
PVCT
Provectus Biopharmaceuticals
0.6$0.07+1.7%$26.88 millionN/A0.00
Pharmaxis logo
PXSLY
Pharmaxis
0.6$1.00+4.7%$26.39 million$8.75 million0.00Gap Down
AngioSoma logo
SOAN
AngioSoma
1.0$0.05+7.7%$26.16 millionN/A0.00Gap Up
SXTC
China SXT Pharmaceuticals
0.4$1.61+1.2%$24.98 million$5.16 million0.00
Mateon Therapeutics logo
MATN
Mateon Therapeutics
1.5$0.26+7.7%$24.37 millionN/A0.00Gap Up
Benitec Biopharma logo
BNTC
Benitec Biopharma
1.2$4.97+1.0%$23.95 million$100,000.00-0.61Gap Up
Artelo Biosciences logo
ARTL
Artelo Biosciences
1.2$1.52+3.9%$23.88 millionN/A-1.50Upcoming Earnings
Gap Up
Q BioMed logo
QBIO
Q BioMed
0.5$0.92+0.5%$23.78 millionN/A-1.41
AMAR
Amarillo Biosciences
0.5$0.51+18.6%$22.30 million$10,000.000.00Gap Down
Millendo Therapeutics logo
MLND
Millendo Therapeutics
1.5$1.16+4.3%$22.09 millionN/A-0.48
NTN Buzztime logo
NTN
NTN Buzztime
0.4$2.70+1.1%$19.14 million$19.81 million-1.31Gap Up
Xenetic Biosciences logo
XBIO
Xenetic Biosciences
1.5$2.17+0.5%$18.98 million$20,000.000.00
Bellicum Pharmaceuticals logo
BLCM
Bellicum Pharmaceuticals
1.3$3.59+5.0%$18.17 million$7.14 million-0.27
Bioxytran logo
BIXT
Bioxytran
0.0$0.18+5.6%$18.12 millionN/A0.00Gap Down
Sonoma Pharmaceuticals logo
SNOA
Sonoma Pharmaceuticals
0.5$8.59+0.1%$17.84 million$18.94 million-9.65
XTLB
XTL Biopharmaceuticals
0.6$3.28+2.4%$16.86 millionN/A-5.29Gap Up
NMUS
Nemus Bioscience
0.6$0.65+10.5%$16.07 millionN/A0.00High Trading Volume
Eledon Pharmaceuticals logo
ELDN
Eledon Pharmaceuticals
1.6$11.13+2.9%$15.98 millionN/A-0.50
Novus Therapeutics logo
NVUS
Novus Therapeutics
1.3$14.60+5.5%$15.98 millionN/A-0.65
Intec Pharma logo
NTEC
Intec Pharma
1.4$4.26+2.1%$15.30 millionN/A-0.60Gap Up
BetterLife Pharma logo
BETRF
BetterLife Pharma
0.0$0.81+0.2%$13.91 millionN/A-1.08
NRIFF
Nuvo Pharmaceuticals
0.7$0.75+0.4%$13.79 million$52.41 million18.69
NVLNF
Novelion Therapeutics
0.6$0.70+1.2%$13.77 million$130.43 million0.00Gap Down
Teligent logo
TLGT
Teligent
1.2$0.62+0.6%$13.46 million$65.90 million-0.07
MedAvail logo
MDVL
MedAvail
1.8$12.99+0.2%$13.20 million$1.03 million-3.18Analyst Downgrade
Medicure logo
MCUJF
Medicure
0.6$1.28+5.1%$13.12 million$15.20 million-1.02Gap Down
CannaPharmaRX logo
CPMD
CannaPharmaRX
0.3$0.24+0.5%$12.54 millionN/A-0.47
CannaPharmaRX logo
CPMD
CannaPharmaRX
0.3$0.24+0.5%$12.54 millionN/A-0.47
iCo Therapeutics logo
ICOTF
iCo Therapeutics
0.5$0.08+1.5%$11.99 millionN/A-3.90Gap Up
Nexien BioPharma logo
NXEN
Nexien BioPharma
0.0$0.20+2.4%$11.16 millionN/A0.00
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.